Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation

ALAD predominantly occurs in the early post-transplant period. This project aims to establish a systematic framework for monitoring and predicting post-lung transplant dysfunction, with a specific focus on acute lung allograft dysfunction (ALAD) and its progression to chronic lung allograft dysfunction (CLAD). We plan to conduct a prospective, multicenter clinical cohort study, longitudinally collecting peripheral blood and bronchoalveolar lavage fluid (BALF) samples from transplant recipients at various time points. By integrating multi-omics technologies-including cfDNA fragmentomics, peripheral blood single-cell sequencing, and proteomic mass spectrometry-with pulmonary function (FEV1) and clinicopathological data, we seek to delineate the dynamic landscape of post-lung transplant dysfunction. Compared to previous studies that relied on single indicators or one-time measurements, this project is distinguished by several key features: Firstly, the use of cfDNA fragmentomic characteristics to infer tissue origin, enabling highly specific detection of graft injury without requiring donor genotype information. Secondly, the integration of single-cell transcriptomics to comprehensively analyze the dynamics of peripheral immune cell subsets, providing a basis for early immunological warning of dysfunction. Thirdly, the application of proteomics to reveal expression levels, post-translational modifications, and protein-protein interactions in plasma samples. Fourthly, the construction of a multi-dimensional integrated model incorporating blood, BALF, and pulmonary function data, with the goal of establishing a generalizable early warning system. Through this research, we aim not only to enhance the early identification and intervention of ALAD but also to lay the foundation for elucidating the molecular mechanisms underlying CLAD development and exploring potential therapeutic targets.

Inclusion criteria

• Recipients aged ≥18 years undergoing single or double lung transplantation;
• Postoperative recipients capable of understanding and providing written informed consent, and willing to comply with scheduled follow-ups and sample collections as required by the study;
• Postoperative recipients clinically assessed as stable and eligible for routine follow-up and hematological examinations;
• Recipients able to undergo dynamic pulmonary function monitoring during follow-up;
• No planned participation in other interventional trials during the study period that may impact immune function or pulmonary function;
• Retransplant patients will be considered as a new transplant event and may be included in the analysis.

Exclusion criteria

• History of active malignancy or presence of untreated malignancy within 5 years prior to transplantation;
• Presence of active systemic infection or significant immune rejection;
• Female patients who are pregnant or lactating;
• Any other condition deemed by the investigator to be inappropriate for inclusion .